Xeris Biopharma Holdings, Inc. (XERS)
- Previous Close
2.8800 - Open
2.8600 - Bid 2.7700 x 500
- Ask 2.8400 x 200
- Day's Range
2.7343 - 2.8800 - 52 Week Range
1.4600 - 3.2600 - Volume
1,457,261 - Avg. Volume
1,474,800 - Market Cap (intraday)
415.707M - Beta (5Y Monthly) 1.30
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4200 - Earnings Date Nov 8, 2024 - Nov 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.67
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
www.xerispharma.comRecent News: XERS
View MorePerformance Overview: XERS
Trailing total returns as of 8/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XERS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XERS
View MoreValuation Measures
Market Cap
429.12M
Enterprise Value
621.35M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.24
Price/Book (mrq)
--
Enterprise Value/Revenue
3.43
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-32.83%
Return on Assets (ttm)
-7.04%
Return on Equity (ttm)
--
Revenue (ttm)
181.41M
Net Income Avi to Common (ttm)
-59.56M
Diluted EPS (ttm)
-0.4200
Balance Sheet and Cash Flow
Total Cash (mrq)
77.57M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-38.89M